Sheng Li1, Jing Liu1, Jianpeng Huang1, Ding Luo1, Qian Wu1, Baile Ning1, Ling Chen1, Jianhua Liu2, Wen-Bin Fu3. 1. Department of Acupuncture and Moxibustion, the 2nd clinical hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. 2. Department of Acupuncture and Moxibustion, the 2nd clinical hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. jianhualiu@gzucm.edu.cn. 3. Department of Acupuncture and Moxibustion, the 2nd clinical hospital of Guangzhou University of Chinese Medicine, Guangzhou, Guangdong, China. fuwenbin@gzucm.edu.cn.
Abstract
BACKGROUND:Depression and chronic musculoskeletal pain (CMSP) are the leading causes of years lived with disabling diseases worldwide. Moreover, they often commonly coexist, which makes diagnosis and treatment difficult. A safe and effective treatment is urgently needed. Previous studies have shown that acupuncture is a cost-effective treatment for simple depression or CMSP. However, there is limited evidence that acupuncture is effective for depression comorbid with CMSP. METHODS: This is a randomized, sham acupuncture-controlled trial with three arms: real acupuncture (RA), sham acupuncture (SA), and healthy control (HC). Forty-eight depression combined CMSP participants and 12 healthy people will be recruited from GDTCM hospital and randomized 2:2:1 to the RA, SA, and HC groups. The patients will receive RA or SA intervention for 8 weeks, and HC will not receive any intervention. Upon completion of the intervention, there will be a 4-week follow-up. The primary outcome measures will be the severity of depression and pain, which will be assessed by the Hamilton Depression Rating Scale (HAMD-17) and Brief Pain Inventory (BPI), respectively. The secondary outcome measures will be cognitive function and quality of life, which will be measured by the Montreal Cognitive Assessment (MoCA), P300, and World Health Organization Quality of Life (WHOQOL-BREF). In addition, the correlation between brain-derived neurotrophic factor (BDNF) and symptoms will also be determined. DISCUSSION: The aim of this study is to evaluate the clinical efficacy and underlying mechanism of acupuncture in depression comorbid with CMSP. This study could provide evidence for a convenient and cost-effective means of future prevention and treatment of combined depression and CMSP. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800014754 . Preregistered on 2 February 2018. The study is currently recruiting.
RCT Entities:
BACKGROUND:Depression and chronic musculoskeletal pain (CMSP) are the leading causes of years lived with disabling diseases worldwide. Moreover, they often commonly coexist, which makes diagnosis and treatment difficult. A safe and effective treatment is urgently needed. Previous studies have shown that acupuncture is a cost-effective treatment for simple depression or CMSP. However, there is limited evidence that acupuncture is effective for depression comorbid with CMSP. METHODS: This is a randomized, sham acupuncture-controlled trial with three arms: real acupuncture (RA), sham acupuncture (SA), and healthy control (HC). Forty-eight depression combined CMSP participants and 12 healthy people will be recruited from GDTCM hospital and randomized 2:2:1 to the RA, SA, and HC groups. The patients will receive RA or SA intervention for 8 weeks, and HC will not receive any intervention. Upon completion of the intervention, there will be a 4-week follow-up. The primary outcome measures will be the severity of depression and pain, which will be assessed by the Hamilton Depression Rating Scale (HAMD-17) and Brief Pain Inventory (BPI), respectively. The secondary outcome measures will be cognitive function and quality of life, which will be measured by the Montreal Cognitive Assessment (MoCA), P300, and World Health Organization Quality of Life (WHOQOL-BREF). In addition, the correlation between brain-derived neurotrophic factor (BDNF) and symptoms will also be determined. DISCUSSION: The aim of this study is to evaluate the clinical efficacy and underlying mechanism of acupuncture in depression comorbid with CMSP. This study could provide evidence for a convenient and cost-effective means of future prevention and treatment of combined depression and CMSP. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR1800014754 . Preregistered on 2 February 2018. The study is currently recruiting.
Authors: Antonio Terracciano; Monia Lobina; Maria Grazia Piras; Antonella Mulas; Alessandra Cannas; Osorio Meirelles; Angelina R Sutin; Alan B Zonderman; Manuela Uda; Laura Crisponi; David Schlessinger Journal: Psychosom Med Date: 2011-09-23 Impact factor: 4.312
Authors: Orla Moriarty; Nancy Ruane; David O'Gorman; Chris H Maharaj; Caroline Mitchell; Kiran M Sarma; David P Finn; Brian E McGuire Journal: Front Behav Neurosci Date: 2017-06-13 Impact factor: 3.558
Authors: Klaus Lieb; Nadine Dreimüller; Stefanie Wagner; Konrad Schlicht; Tanja Falter; Alexandra Neyazi; Linda Müller-Engling; Stefan Bleich; André Tadić; Helge Frieling Journal: Front Psychiatry Date: 2018-10-26 Impact factor: 4.157